Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research

Ravindran Kanesvaran, Raul Cordoba, Ronald Maggiore

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Immunotherapy has expanded the therapeutic landscape for advanced cancers, including solid tumors and lymphomas. For many patients with cancer, these agents have been shown to have substantial efficacy and favorable toxicity compared with cytotoxic agents, particularly in the second-line setting. With the advent of anti-PD-1 and anti-PD-L1 checkpoint inhibitors, combination immunotherapy- and chemoimmunotherapy-based strategies have emerged as promising novel regimens to improve cancer-related outcomes. Older adults age 65 or older represent the growing majority of patients diagnosed with cancer. However, older adults are under-represented in clinical trials in general, as well as in the landmark studies that led to approval of these immunotherapy agents. Because of increasing age and attendant multimorbidity and impaired functional status, many of these patients seen in the community-based oncology practices would not have been considered eligible for such studies. Thus, the results of these studies are difficult to generalize to a broader patient population with these competing risks. Furthermore, robust evaluation of toxicities, effect on quality of life and functional status, and aging-related (i.e., immunosenescence) and immunotherapy-related changes affecting the immune system remain underexplored research areas for older adults. This review examines the role of immunotherapy and its unique issues, specifically in older adults with lung cancer, bladder cancer, and lymphomas.

Original languageEnglish (US)
Pages (from-to)400-414
Number of pages15
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number38
DOIs
StatePublished - May 23 2018
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
Urinary Bladder Neoplasms
Lymphoma
Cytotoxins
Comorbidity
Immune System
Lung Neoplasms
Quality of Life
Clinical Decision-Making
Clinical Trials
Research
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunotherapy in Older Adults With Advanced Cancers : Implications for Clinical Decision-Making and Future Research. / Kanesvaran, Ravindran; Cordoba, Raul; Maggiore, Ronald.

In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, No. 38, 23.05.2018, p. 400-414.

Research output: Contribution to journalReview article

@article{777ddd7f5e754a7d82eb6de0c5095b4f,
title = "Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research",
abstract = "Immunotherapy has expanded the therapeutic landscape for advanced cancers, including solid tumors and lymphomas. For many patients with cancer, these agents have been shown to have substantial efficacy and favorable toxicity compared with cytotoxic agents, particularly in the second-line setting. With the advent of anti-PD-1 and anti-PD-L1 checkpoint inhibitors, combination immunotherapy- and chemoimmunotherapy-based strategies have emerged as promising novel regimens to improve cancer-related outcomes. Older adults age 65 or older represent the growing majority of patients diagnosed with cancer. However, older adults are under-represented in clinical trials in general, as well as in the landmark studies that led to approval of these immunotherapy agents. Because of increasing age and attendant multimorbidity and impaired functional status, many of these patients seen in the community-based oncology practices would not have been considered eligible for such studies. Thus, the results of these studies are difficult to generalize to a broader patient population with these competing risks. Furthermore, robust evaluation of toxicities, effect on quality of life and functional status, and aging-related (i.e., immunosenescence) and immunotherapy-related changes affecting the immune system remain underexplored research areas for older adults. This review examines the role of immunotherapy and its unique issues, specifically in older adults with lung cancer, bladder cancer, and lymphomas.",
author = "Ravindran Kanesvaran and Raul Cordoba and Ronald Maggiore",
year = "2018",
month = "5",
day = "23",
doi = "10.1200/EDBK_201435",
language = "English (US)",
pages = "400--414",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",
number = "38",

}

TY - JOUR

T1 - Immunotherapy in Older Adults With Advanced Cancers

T2 - Implications for Clinical Decision-Making and Future Research

AU - Kanesvaran, Ravindran

AU - Cordoba, Raul

AU - Maggiore, Ronald

PY - 2018/5/23

Y1 - 2018/5/23

N2 - Immunotherapy has expanded the therapeutic landscape for advanced cancers, including solid tumors and lymphomas. For many patients with cancer, these agents have been shown to have substantial efficacy and favorable toxicity compared with cytotoxic agents, particularly in the second-line setting. With the advent of anti-PD-1 and anti-PD-L1 checkpoint inhibitors, combination immunotherapy- and chemoimmunotherapy-based strategies have emerged as promising novel regimens to improve cancer-related outcomes. Older adults age 65 or older represent the growing majority of patients diagnosed with cancer. However, older adults are under-represented in clinical trials in general, as well as in the landmark studies that led to approval of these immunotherapy agents. Because of increasing age and attendant multimorbidity and impaired functional status, many of these patients seen in the community-based oncology practices would not have been considered eligible for such studies. Thus, the results of these studies are difficult to generalize to a broader patient population with these competing risks. Furthermore, robust evaluation of toxicities, effect on quality of life and functional status, and aging-related (i.e., immunosenescence) and immunotherapy-related changes affecting the immune system remain underexplored research areas for older adults. This review examines the role of immunotherapy and its unique issues, specifically in older adults with lung cancer, bladder cancer, and lymphomas.

AB - Immunotherapy has expanded the therapeutic landscape for advanced cancers, including solid tumors and lymphomas. For many patients with cancer, these agents have been shown to have substantial efficacy and favorable toxicity compared with cytotoxic agents, particularly in the second-line setting. With the advent of anti-PD-1 and anti-PD-L1 checkpoint inhibitors, combination immunotherapy- and chemoimmunotherapy-based strategies have emerged as promising novel regimens to improve cancer-related outcomes. Older adults age 65 or older represent the growing majority of patients diagnosed with cancer. However, older adults are under-represented in clinical trials in general, as well as in the landmark studies that led to approval of these immunotherapy agents. Because of increasing age and attendant multimorbidity and impaired functional status, many of these patients seen in the community-based oncology practices would not have been considered eligible for such studies. Thus, the results of these studies are difficult to generalize to a broader patient population with these competing risks. Furthermore, robust evaluation of toxicities, effect on quality of life and functional status, and aging-related (i.e., immunosenescence) and immunotherapy-related changes affecting the immune system remain underexplored research areas for older adults. This review examines the role of immunotherapy and its unique issues, specifically in older adults with lung cancer, bladder cancer, and lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=85057229130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057229130&partnerID=8YFLogxK

U2 - 10.1200/EDBK_201435

DO - 10.1200/EDBK_201435

M3 - Review article

C2 - 30231397

AN - SCOPUS:85057229130

SP - 400

EP - 414

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

IS - 38

ER -